Wedbush Issues Positive Outlook for SWTX Earnings

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Equities researchers at Wedbush increased their Q2 2025 earnings estimates for SpringWorks Therapeutics in a research note issued to investors on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.68) per share for the quarter, up from their previous estimate of ($0.71). Wedbush currently has a “Outperform” rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.03) per share. Wedbush also issued estimates for SpringWorks Therapeutics’ Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

Several other research firms have also recently weighed in on SWTX. Guggenheim decreased their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Evercore ISI increased their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a research report on Wednesday, February 12th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $70.83.

SpringWorks Therapeutics Trading Down 2.0 %

SWTX stock opened at $56.30 on Monday. The company’s 50 day moving average is $39.66 and its 200 day moving average is $37.02. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of -14.51 and a beta of 0.81. SpringWorks Therapeutics has a 1-year low of $28.21 and a 1-year high of $60.00.

Institutional Trading of SpringWorks Therapeutics

A number of institutional investors have recently made changes to their positions in SWTX. Boxer Capital Management LLC purchased a new stake in shares of SpringWorks Therapeutics during the fourth quarter valued at approximately $123,620,000. Capital International Investors lifted its stake in SpringWorks Therapeutics by 92.7% in the fourth quarter. Capital International Investors now owns 2,361,746 shares of the company’s stock worth $85,330,000 after acquiring an additional 1,136,079 shares during the period. Pictet Asset Management Holding SA lifted its stake in SpringWorks Therapeutics by 24.2% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company’s stock worth $86,402,000 after acquiring an additional 465,494 shares during the period. Principal Financial Group Inc. lifted its stake in SpringWorks Therapeutics by 102.5% in the third quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock worth $29,427,000 after acquiring an additional 464,903 shares during the period. Finally, Vanguard Group Inc. lifted its stake in SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company’s stock worth $258,650,000 after acquiring an additional 445,593 shares during the period.

Insider Buying and Selling at SpringWorks Therapeutics

In other news, Director Daniel Lynch sold 175,000 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $54.46, for a total transaction of $9,530,500.00. Following the completion of the sale, the director now owns 130,944 shares of the company’s stock, valued at approximately $7,131,210.24. This represents a 57.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Badreddin Edris sold 20,000 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total value of $839,400.00. Following the sale, the chief operating officer now directly owns 209,600 shares of the company’s stock, valued at approximately $8,796,912. This trade represents a 8.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 302,750 shares of company stock worth $16,139,410 over the last ninety days. Insiders own 7.61% of the company’s stock.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.